Text Size

Glucose Regulation in Acute Stroke Patients (GRASP) Study

This study has been completed.
Sponsor:
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:
University of Virginia
ClinicalTrials.gov Identifier:
NCT00282867
First received: January 26, 2006
Last updated: July 15, 2009
Last verified: July 2009
History of Changes
Results First Received: July 14, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Stroke
Hyperglycemia
Interventions: Drug: IV glucose insulin and potassium, GIK
Other: standard care

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Tight Control Group target glucose level 70-110 mg/dL
Loose Control Group target glucose level 70 – 200 mg/dL
Usual Care Group target level 70 - 300 mg/dL

Participant Flow:   Overall Study
    Tight Control Group     Loose Control Group     Usual Care Group  
STARTED     24     25     25  
COMPLETED     23     24     25  
NOT COMPLETED     1     1     0  
d/c prior to prim outcome, 3 m f/u done                 1                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Tight Control Group target glucose level 70-110 mg/dL
Loose Control Group target glucose level 70 – 200 mg/dL
Usual Care Group target level 70 - 300 mg/dL
Total Total of all reporting groups

Baseline Measures
    Tight Control Group     Loose Control Group     Usual Care Group     Total  
Number of Participants  
[units: participants]
 		  24     25     25     74  
Age  
[units: participants]
 		       
<=18 years     0     0     0     0  
Between 18 and 65 years     11     8     12     31  
>=65 years     13     17     13     43  
Gender  
[units: participants]
 		       
Female     11     12     10     33  
Male     13     13     15     41  
Region of Enrollment  
[units: participants]
 		       
United States     24     25     25     74  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Hypoglycemic Events   [ Time Frame: up to 5 days ]
  Show Outcome Measure 1

2.  Secondary:   Favorable 3 Month Modified Rankin   [ Time Frame: 3 months ]
  Show Outcome Measure 2

3.  Other Pre-specified:   Symptomatic Hypoglycemia   [ Time Frame: up to 5 days ]
  Show Outcome Measure 3

4.  Post-Hoc:   Target Glucose Concentration   [ Time Frame: first 24 hours after initiation of treatment ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Karen C. Johnston, MD, MSc
Organization: University of Virginia
phone: 434 924-5323
e-mail: kj4v@virginia.edu


No publications provided


Responsible Party: Karen C. Johnston, MD, MSc, PI, Professor and Chair Department of Neurology, University of Virginia
ClinicalTrials.gov Identifier: NCT00282867     History of Changes
Other Study ID Numbers: 11901, R01NS050192
Study First Received: January 26, 2006
Results First Received: July 14, 2009
Last Updated: July 15, 2009
Health Authority: United States: Federal Government